{{Rsnum
|rsid=3213422
|Gene=DHODH
|Chromosome=16
|position=72008783
|Orientation=plus
|ReferenceAllele=A
|MissenseAllele=C
|GMAF=0.4302
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;C)
|geno3=(C;C)
|Gene_s=DHODH
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;C)
| geno3=(C;C)
| CEU | 22.1 | 51.3 | 26.5
| HCB | 8.8 | 34.6 | 56.6
| JPT | 11.5 | 37.2 | 51.3
| YRI | 22.4 | 54.4 | 23.1
| ASW | 21.1 | 36.8 | 42.1
| CHB | 8.8 | 34.6 | 56.6
| CHD | 2.8 | 45.0 | 52.3
| GIH | 32.7 | 44.6 | 22.8
| LWK | 33.3 | 58.3 | 8.3
| MEX | 12.1 | 48.3 | 39.7
| MKK | 23.7 | 51.3 | 25.0
| TSI | 26.5 | 51.0 | 22.5
| HapMapRevision=28
}}{{PMID|19207032}} The frequency of remission from [[rheumatoid arthritis]] upon leflunomide treatment was increased in [[rs3213422]](C) allele carriers compared with patients with the A allele in a study of 147 patients.

{{PharmGKB
|RSID=rs3213422
|Name_s=DHODH: 19C>A; Gln7Lys
|Gene_s=PKD1L3, DHODH
|Feature=
|Evidence=PubMed ID:19207032
|Annotation=This variant is associated with leflunomide treatment outcome in a study consisting of 147 patients with rheumatoid arthritis. The C allele carriers tend to have increased frequency of remission compared with patients with the A allele.
|Drugs=leflunomide
|Drug Classes=
|Diseases=Arthritis, Rheumatoid
|Curation Level=Curated
|PharmGKB Accession ID=PA162630418
}}

{{GET Evidence
|gene=DHODH
|aa_change=Lys7Gln
|aa_change_short=K7Q
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs3213422
|overall_frequency_n=5297
|overall_frequency_d=9766
|overall_frequency=0.542392
|n_genomes=47
|n_genomes_annotated=0
|n_haplomes=66
|n_articles=1
|n_articles_annotated=1
|in_pharmgkb=Y
|pph2_score=0.004
|nblosum100=-2
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}